We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Oxidative Stress in Alzheimer's Disease: Pathogenesis, Biomarkers and Therapy

Alejandro Gella and Irene Bolea
Universitat Internacional de Catalunya
Universitat Autònoma de Barcelona
 Spain

1. Introduction

Alzheimer's disease (AD) is the most common cause of dementia in the elderly with profound medical and social consequences. The pathogenesis of AD is a complex and heterogeneous process which classical neuropathological hallmarks found in the brain are extracellular deposits of beta-amyloid (A β)-containing plaques and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein. Mutation of *presenilin-1* (PS-1), *presenilin-2* (PS-2), and altered *amyloid precursor protein* (APP) genes has been reported to cause inherited AD. In addition, other genes such as apolipoprotein E-4 (APOE), endothelial nitric oxide synthase-3, and alpha-2-macroglobulin have also been associated with AD. A further number of hypothesis have been proposed for AD mechanism, which include: the amyloid cascade, vascular damage, excitotoxicity, deficiency of neurotrophic factors, mitochondrial dysfunction, trace element neurotoxicity, inflammation and oxidative stress hypothesis.

The oxidative stress (OS) hypothesis of aging postulated by Dr. Denham Harman in 1956 proposed that brain aging is associated to a progressive imbalance between the anti-oxidant defenses and the pro-oxidant species that can occur as a result of either an increase in free radical production or a decrease in antioxidant defence. The fact that age is the main risk factor for AD development provides considerable support to the OS hypothesis since the effects produced by reactive oxygen species (ROS) can accumulate over the years (Nunomura et al., 2001). The link between AD and OS is additionally supported by the finding of decreased levels of antioxidant enzymes, increased protein, lipid and DNA oxidation and advanced glycation end products (AGEs) and ROS formation in neurons of AD patients (Perry et al., 2000; Barnham et al., 2004). It has been reported that the accumulation of the oligomeric form of A β , the most toxic form of the peptide, induces OS in neurons (Butterfield, 2002), supporting the hypothesis and suggesting that OS plays a causative role in the development of AD. Then, a large amount of literature has demonstrated that OS is an important feature in AD pathogenesis that deserves to be deeply studied (Perry et al, 2002; Markesbery et al, 1999). In this Chapter, we address the main factors involved in the generation of oxidative stress and provide an overview of the oxidative stress biomarkers status in Alzheimer's disease. The Chapter concludes with a revision of the controversial efficacy of antioxidants as potential treatment in AD therapy as well as an update of the main antioxidant compounds found to have a beneficial effect in AD.

2. Mitochondria as a source of reactive oxygen species

Several years after the postulation of the OS hypothesis, Dr. Harman proposed that life span is determined by the rate of ROS damage to the mitochondria (Harman, 1972) giving for the first time an important role to this organelle in the ageing process and establishing the basis for “mitochondrial theory of ageing”. It is important to note that the central nervous system (CNS) is especially vulnerable to oxidative damage as a result of the high oxygen consumption rate (20% of the total oxygen consumption), the abundant content of easily peroxidizable fatty acids, and the relative paucity of antioxidant enzymes compared to other tissues. In aerobic organisms, mitochondria produce semireduced oxygen species during respiration. The initial step of the respiratory chain reaction yields the superoxide radical ($^{\bullet}\text{O}_2^-$), which produces hydrogen peroxide (H_2O_2) by addition of an electron. The reduction of H_2O_2 through the Fenton reaction produces the highly reactive hydroxyl radical ($^{\bullet}\text{OH}$), which is the chief instigator of oxidative stress damage and reacts indiscriminately with all biomacromolecules (Figure 1). Under normal conditions, damage by ROS is prevented by an efficient antioxidant cascade, including both enzymatic and non-enzymatic entities. The enzymes responsible of the detoxification machinery are the cytosolic copper-zinc superoxide dismutase (CuZnSOD) and the mitochondrial manganese superoxide dismutase (MnSOD), which convert superoxide to O_2 and H_2O_2 . Moreover, monoamine oxidases (MAOs) and L-amino acid oxidase can also produce H_2O_2 during its metabolism which is effectively removed by catalase (CAT) and peroxidases (e.g. glutathione peroxidase, GPx). Since CAT is compartmentalized into peroxisomes the detoxification of cytosolic and mitochondrial peroxides depends predominantly on GPx.

Fig. 1. Schematic illustration of the mechanism involved in reactive oxygen species (ROS) formation and elimination. Glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase (SOD), catalase (CAT), monoamine oxidase (MAO), glutathione (GSH), glutathione disulfide (GSSG).

The non-enzymatic antioxidant defenses include the reduction of the resulting oxidized transition metal ions (usually Fe^{3+} and Cu^{2+}) by cellular reductants such as vitamin C, thiols and perhaps even vitamin E. In this context, SOD can also serve as the reductant of oxidized metal ions for the production of hydroxyl radical from H_2O_2 , which coupled with the Fenton reaction, is known as the Haber-Weiss reaction. In AD, this situation is further exacerbated by the fact that redox active transition metals are aberrantly accumulated in cytoplasm of

neurons. Moreover, A β peptide is considered a strong redox active agent capable of reducing transition metals and allowing for conversion of O₂ to H₂O₂ (Bondy et al, 1998).

3. Biomarkers of oxidative stress in Alzheimer’s disease

Biomarkers, as indicators of signalling events in biological systems or samples, can be used as intermediate endpoints or early-outcome predictors of disease development for preventive purposes. Most effort is nowadays focused on the search of reliable and robust biomarkers which would be useful for an earlier AD diagnosis. The emphasis is being placed on the incorporation of oxidative stress biomarkers to study the increased oxidative damage (Lovell & Markesbery, 2007a). It has recently been a significant improvement in assay methods and measurement accuracy for oxidative biomarkers. Nevertheless, it appears imperative that biomarkers of oxidative damage must be validated (Dalle-Donne et al., 2006a) in order to incorporate them into epidemiological studies and provide a better understanding regarding the role of ROS in the pathogenesis and progression of AD, as well as to assess the possible effectiveness of an antioxidant therapy (Griffiths et al., 2002). Strong evidence show that oxidative markers are more prevalent in initial rather than in later stages of the disease, and thus suggesting that targeting the earlier events of the disease may be more successful than targeting the later events (e.g. beta-amyloid (A β) plaque deposition and/or intracellular neurofibrillary tangles formation). On the other hand, many studies provided evidence for the deleterious consequences of oxidative stress products on certain cellular targets in AD. Therefore, most highly reactive oxidants react with virtually all biomolecules, including, lipids, DNA/RNA, carbohydrates and proteins. Table 1 summarizes the main OS biomarker candidates for MCI and AD diagnosis.

Biomarker	Specimen	Diagnosis	Reference
Lipid Peroxidation			
4-HNE	Plasma	AD	Mc Grath et al., 2001
	Ventricular fluid	AD	Lovell et al., 1997
F2-Isoprostanes	Urine	AD	Kim et al., 2004
	CSF	AD	Montine et al., 2011
	CSF, plasma and urine	MCI	Pratico et al., 2002
DNA oxidation			
8-OHdG	Peripheral lymphocytes	MCI	Migliore et al., 2005
		AD	Mecocci et al., 2002
AGEs			
CML	CSF	AD	Ahmed et al., 2005
Oxidized Protein			
α -1-antitrypsin	CSF	AD	Puchades et al., 2003
Ig λ light chain	CSF	MCI	Korolainen et al., 2007
α -1-antitrypsin	Plasma	AD	Yu et al., 2003; Choi et al., 2002

Table 1. Potential OS biomarkers under validation for Alzheimer’s disease. MCI, mild cognitive impairment; AD, Alzheimer’s disease; CSF, cerebrospinal fluid; Ig, immunoglobulin; 4-HNE, 4-hydroxy-2-nonenal; 8-OHdG, 8-oxo-7,8-dihydro-2’-deoxyguanosine; AGEs, Advanced Glycation end products; CML, N-carboxymethyl-lysine.

3.1 Biomarkers of lipid peroxidation

Lipid oxidation (also called lipid peroxidation) has dramatic consequences in ageing and age-related disorders. Phospholipids present in brain membranes are mainly polyunsaturated fatty acids (PUFAs: arachidonic acid, linoleic acid, linolenic acid, docosahexaenoic acid, etc...), which are especially vulnerable to a free radical attack since their double bonds allow an easy removal of hydrogen ions. Oxidation of PUFAs produces a variety of reactive α,β -unsaturated aldehydes such as, acrolein, 4-hydroxy-2-nonenal (4-HNE), 4-oxo-2-nonenal (4-ONE), 4-hydroxy-2-hexenal (4-HHE), 2-hexenal, crotonaldehyde as well as the dialdehydes glyoxal and malondialdehyde (MDA). These species are highly reactive cytotoxic substances than can form stable covalent adducts with free amino groups of proteins (Lys, His and Cys residues) through Michael addition (Calingasan et al., 1999; Carini et al., 2004; Esterbauer et al., 1991; Montine et al., 1997) which are known as advanced lipoxidation end products (ALEs). 4-HNE is a major and toxic aldehyde generated by free radical attack on PUFAs and is considered a second toxic messenger of oxygen free radicals. Therefore, it has a high biological activity and exhibits numerous cytotoxic, mutagenic, genotoxic, and signalling effects in neurons (Eckl et al., 1993; Williams et al., 2006). In addition, 4-HNE may be an important mediator of OS-induced apoptosis, cellular proliferation and signalling pathways (Uchida, 2003). HNE is permanently formed at basal concentrations under physiologic conditions, but its production is greatly enhanced in the AD brain where increased lipid peroxidation occurs (Butterfield et al., 2010; McGrath et al., 2001). Increased concentrations of 4-HNE, 4-HHE and acrolein have been found in cerebrospinal fluid (CSF) and in multiple brain regions from individuals with mild cognitive impairment and early AD compared with age-matched controls (Bradley et al., 2010a and 2010b; Lovell et al., 1997; Williams et al., 2006). In addition, a positive feedback in the pathogenesis of AD is provoked by HNE that increases $A\beta$ production (Tamagno et al., 2008) which, in turns, induces lipid peroxidation (Butterfield et al., 2002). Furthermore, HNE-adducts have been identified in amyloid plaques and neurofibrillary tangles, the two hallmarks of AD pathogenesis (Sayre et al., 1997; Ando et al., 1998; Wataya et al., 2002).

Fig. 2. Lipid peroxidation products. ROS stimulate peroxidation of polyunsaturated fatty acids (PUFA) to generate α,β -unsaturated aldehydes and dialdehydes.

F2-Isoprostanes (F2-IsoPs), which contain an F-type prostane ring, are a group of bioactive prostaglandin-like compounds generated via a non-enzymatic mechanism involving the free radical-initiated peroxidation of esterified arachidonic acid (AA). Then, they are cleaved and released into the circulation by phospholipases before excretion in the urine as free

isoprostanes (Basu, 1998). The most studied class of isoprostanes, due to their urine stability, is 8-iso-Prostaglandin F_{2a} (8-iso-PGF $_{2a}$; Figure 3). Urinary F2-IsoPs determination has been proposed as specific, reliable, and non-invasive marker to assess lipid peroxidation *in vivo* (Cracowski et al., 2002; Montushchi et al., 2004) since an increase in 8-iso-PGF $_{2a}$ levels in CSF and urine have been found in subjects with AD (Montine et al., 1998 and 2011; Kim et al., 2004). On the other hand, oxidation of docosahexanoic acid (DHA) produces F4-neuroprostanes (F4-NeuroPs; Figure 3) (Morrow et al., 1999; Roberts et al., 1998) which levels are elevated in postmortem ventricular CSF of AD patients and are more abundant in the brain than F2-isoprostanes. Nevertheless, plasma F2-IsoPs and F4-NeuroPs do not accurately reflect central nervous system levels and are not reproducibly elevated in body fluids outside of central nervous system in Alzheimer's disease patients (Montine et al., 2002).

Fig. 3. Chemical structures of F4-neuropropane and 8-iso-Prostaglandin F_{2a} arising from direct oxidation of docosahexanoic and arachidonic acids, respectively.

3.2 Biomarkers of oxidative DNA damage

Among over 30 nucleobase modifications that have been described, the most extensively studied that reflect oxidative DNA damage is 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG; also known as 8-OHdG), a product of oxidatively modified DNA base guanine (Figure 4). The detection of this oxidation is important not only due to its abundance but also to its mutagenic potential through GC-to-TA transversion mutations upon replication of DNA (Cheng et al., 1992). Nevertheless, oxidatively damaged DNA can be repaired and released into the bloodstream and consequently appear without further metabolism in the urine (Fraga et al., 1990; Shigenaga et al., 1989). In addition, urinary levels of 8-OHdG have been found to be independent of dietary influence in humans. The modified base 8-oxo-7,8-dihydroguanine (8-oxoGua; Figure 4) and modified nucleoside (8-oxodG; Figure 4), which are found in urine, represent the major repair products of oxidatively damaged DNA *in vivo* and have been considered to reflect the whole-body oxidative DNA damage (Hamilton et al., 2001; Olinnski et al., 2007). There is considerable evidence supporting that oxidative stress occurs in AD, and increased 8-oxodG levels have been found in DNA isolated from brain tissues, leukocytes and ventricular CSF of AD patients. In contrast, free 8-OHdG was found dramatically decreased in AD samples as compared to the controls (Lovell & Markesbery, 2001; Markesbery & Carney, 1999; Mecocci et al., 2002; Migliore et al., 2005).

Taken together, these data indicate a double insult in AD patients by increasing oxidative damage and decreasing DNA repair mechanisms efficiency. More recent studies showed an elevated 8-OHdG in both nuclear and mitochondrial DNA (mtDNA) isolated from vulnerable brain regions in amnesic mild cognitive impairment (MCI), the earliest clinical manifestation of AD, and thus suggesting that oxidative DNA damage is an early event in AD and is not merely a secondary phenomenon (Lovell & Markesbery, 2007b).

Many methods such as HPLC-ECD, GC-MS, LC-MS, and immunoassay have been established to measure 8-OHdG in biological specimens. In this concern, the European Standards Committee of Urinary (DNA) Lesions Analysis (ESCUA) was formed in 2006 in order to validate the measurement methods of oxidatively damaged DNA and to establish reference urine values (Cooke et al., 2008; Evans et al., 2010). Finally, it is important to mention that DNA can also be modified by products of lipid peroxidation (ALEs). These α - β -unsaturated aldehydes can react with deoxyguanosine through an initial Michael addition of the exocyclic amino group followed by ring closure of N-1 onto the aldehydic group to generate a bulky exocyclic 1-N²-propanodeoxyguanosine adduct (Liu et al., 2006; Kozekov et al., 2003) and therefore participate in the propagation of the oxidative DNA damage.

Fig. 4. Chemical structure of 8-oxo-7, 8-dihydro-2'-deoxyguanosine (8-oxodG; 8-OHdG), guanine and 8-oxo-7, 8-dihydroguanine (8-oxoGua).

3.3 Advanced glycation end products

Advanced glycation end products (AGEs), formed by a non-enzymatic reaction of sugars with amino groups in long-lived proteins, lipids, and nucleic acids, are also potent neurotoxins and proinflammatory molecules. Glycation of proteins starts as a non-enzymatic process with the spontaneous condensation of ketone or aldehyde groups of sugars with a free aminoacid group of proteins to form a labile Schiff base, consistent with the classical reaction described by Louis Camille Maillard in 1912 (Figure 5).

Fig. 5. Non-enzymatic reaction of the carbonyl groups of reducing sugars with primary amino groups produce corresponding Schiff bases, which undergo Amadori rearrangement to give ketoamines.

Glycation is the first step in the cascade of a complex series of very slow reactions in the body known as Amadori reactions, Schiff base reactions and Maillard reactions, all leading to the formation of irreversibly cross-linked heterogeneous aggregates. AGEs are continuously formed in the human body and progressively accumulate with age in plasma and tissues. In diabetes mellitus and AD the rate of AGEs formation is accelerated and consequently, they have been considered potentially useful biomarkers for monitoring the treatment of these disorders. Chemical structures of representative markers of AGEs are summarized in Figure 6. Supporting the argument that AGEs are involved in the pathogenesis of AD, some studies have shown the presence of AGEs in association with two major proteins of AD, A β and MAP-tau (Smith et al., 1995; Vitek et al., 1994; Yan et al., 1994). Extracellular AGEs accumulation has been demonstrated in senile plaques in different cortical areas. Intracellular proteins deposits including NFTs, Lewy bodies of patients with Parkinson's disease and Hirano bodies are also crosslinked by AGEs, which may explain their insolubility in detergents and resistance to proteases (Loske et al., 2000). The major component of the NFTs, the microtubuli-associated protein tau (MAP-tau) has been shown to be subject to intracellular AGEs formation. MAP-tau

Fig. 6. A variety of highly reactive carbonyl intermediates such as 3-deoxy-glucosone, glyoxal and methyl-glyoxal can be formed by glucose or Schiff's base or Amadori product auto-oxidation which, in turn, can react with free amino groups to form AGE products. N-carboxymethyl-lysine (CML), N-carboxyethyl-lysine (CEL), glyoxal-derived lysine dimer (GOLD), methylglyoxal-derived lysine dimer (MOLD), furoyl-furanyl-imidazole (FFI), Lysine (Lys) and arginine (Arg).

can be glycosylated in vitro, inhibiting its ability to bind to microtubules. In addition, MAP-tau isolated from brains of AD patients is glycosylated in the tubulin-binding region, giving rise to the formation of β -sheet fibrils (Ledesma et al., 1998). AGEs accumulate in the human brain during aging (Kimura et al., 1996) and are present in neurofibrillary tangles and senile plaques in patients with AD (Castellani et al., 2001). Furthermore; AGE-modified A β peptides accelerate aggregation of soluble nonfibrillar A β peptides. In older adults with cerebrovascular disease, elevated N-carboxymethyl-lysine (CML) has been found in cortical neurons and cerebral vessels and has been related to the severity of cognitive impairment (Southern et al., 2007). Brain tissue AGEs can therefore be considered tissue biomarkers for AD, and increased brain AGEs concentrations are reflected in CSF (Ahmed et al., 2005) but not necessarily in plasma (Thome et al., 1996).

A positive feedback loop in the pathogenesis of AD is provoked by AGEs which increase OS and inflammation through binding with AGEs receptor (RAGE). The RAGE signalling pathway, found upregulated in AD brains, can be initiated by a diverse repertoire of pro-inflammatory ligands that include AGEs, S100/calgranulins, amphotericin, and amyloid- β peptide. Ligand binding with RAGE triggers the induction of increased reactive oxygen species, activates NADH oxidase, increases the expression of adhesion molecules, and up-regulates inflammation through NF- κ B and other signalling pathways.

3.4 Biomarkers of oxidative protein damage

Carbonylation of proteins is an irreversible oxidative process, often leading to a loss of protein function, which is considered a widespread indicator of severe oxidative damage and disease-derived protein dysfunction (Dalle-Donne et al., 2006). Protein carbonyl groups are introduced to proteins by direct oxidation of several amino acid residues into ketone or aldehyde derivatives (particularly lysine, arginine, threonine and proline; Figure 7) or by secondary reaction with the primary oxidation products of sugars (forming AGEs) and lipids (forming ALEs) (Berlett & Stadtman, 1997). Several studies have proved that proteins are major initial cell targets of ROS, leading to earlier formation of the protein carbonyls in biological systems. Detection of increased levels of protein carbonyls in AD has been proposed as a sign of disease-associated dysfunction, suggesting the potentiality as biomarkers for early AD diagnosis.

Recent studies show an increase in protein carbonyls together with NFTs in multiple brain regions of AD subjects (Sultana & Butterfield, 2011). Oxidative modifications of proteins can cause cross-linking of covalent bonds of proteins leading to fibril formation and insolubility. NFTs are characterized by the aggregation and hyperphosphorylation of tau proteins which is linked to oxidation through the microtubule-associated protein kinase pathway and through the activation of the transcription factor NF- κ B. A wide number of studies have reported differences in specific carbonylated proteins in brain, plasma and CSF of AD patients compared with control group by using 2-dimensional gel electrophoresis in combination with mass spectroscopy techniques (Castegna et al., 2002a, 2002b; Davidsson et al., 2001; Puchades et al., 2003). Some of these studies reveal the presence of specific targets of protein oxidation in AD brain: creatine kinase BB, glutamine synthase, ubiquitin carboxy-terminal hydrolase L-1, dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. Glutamine synthase and creatine kinase, both markedly decreased in AD brains, are especially sensitive to oxidative modifications since they may cause alteration of glutamate concentrations (glutamine synthase), and therefore enhance excitotoxicity, and decrease

energy metabolism (creatine kinase). Recently, several oxidized carbonylated proteins have been characterized in frontal cortex (Korolainen et al., 2006), plasma (Yu et al., 2003; Choi et al., 2002) and CSF (Korolainen et al., 2007) of patients suffering from AD by two-dimensional oxyblotting technique.

Fig. 7. Chemical structures of protein carbonyls arising from direct oxidation of amino acid side chains. Glutamic semialdehyde (resulting from direct oxidation of arginyl and prolyl residues) and amino adipic semialdehyde (resulting from direct oxidation of lysyl residue).

4. Antioxidant therapies in Alzheimer's disease

Currently, the only Food and Drug Administration (FDA) approved treatment for AD is the administration of the cholinesterase inhibitors (AChEI) donepezil, galantamine and rivastigmine and the N-methyl-D-aspartate (NMDA) receptor antagonist, memantine (Birks et al., 2000, 2006; Loy et al., 2004; Areosa et al., 2005). Nevertheless, to date, these drugs have demonstrated to produce only modest symptomatic improvements in some of the patients, but not to cure or stop the disease progression. Moreover, AChEI are expensive and may have side effects resulting from activation of peripheral cholinergic systems (Green et al., 2005). Then, effective treatments are greatly needed. The current therapeutic strategies being investigated for AD include targeting neurotransmission with multifunctional compounds, anti-amyloid and anti-tau therapies, drugs targeting mitochondrial dysfunction, neurotrophins, statins and also other approaches such as PUFAs and antioxidants (for review see Mangialasche et al., 2010). Among them, antioxidant therapies and PUFAs are particularly attractive due to their low toxicity, low cost and their ability to target earlier changes of the disease (e.g oxidative stress) which are linked to cognitive and functional decline. However, there is still much skepticism regarding the likelihood of success with an

antioxidant therapy since to date these compounds tested in randomised controlled trials (RCTs) have given controversial results.

4.1 Vitamins

A large amount of literature exists in relation to the potential benefits of vitamins, which act as natural free radical scavengers, in the prevention of AD (Figure 8). Vitamin A has been traditionally considered as antioxidant and it seems essential for learning, memory and cognition. Retinoic acid, a metabolic product of vitamin A, is known to slow cell death and protect from A β (Sahin et al., 2005). Thus, since levels of vitamin A decline with age and are found lower in AD individuals (Goodman et al., 2006) vitamin A supplementation might be useful for the treatment of some features in the ageing process. B-vitamins (B₆, B₁₂ and folic acid) are lipid soluble antioxidants involved in the methylation of homocysteine (Hcy) which is highly cytotoxic. Cellular catabolism and cellular export mechanisms are the responsible for keeping low intracellular Hcy concentration. AD patients typically present high levels of Hcy (McIlroy et al., 2002) and low levels of vitamin B₁₂ and folate which appear to be associated with an increased rate of cognitive decline (Tucker et al., 2006; Morris et al., 2007). Nevertheless, in a recent study, a combination of vitamins B₁₂, B₆ and folate in mild to moderate AD individuals, although lowering Hcy, did not produce any effect on cognition compared to controls. Vitamin C (ascorbic acid), found in many fruits and vegetables, is the major water-soluble antioxidant and acts as first defence against free radicals in blood and plasma. Bagi et al, 2003, have shown that chronic vitamin C treatment is able to decrease high levels of isoprostanes in animal models. In contrast, other studies have shown that it can also act as pro-oxidant inducing neuronal oxidative stress via its

Fig. 8. Chemical structures of the principal polyphenols, herbal supplements and vitamins investigated as promising agents for the treatment of AD.

interaction with metal ions (White et al., 2004). Vitamin E (α -tocopherol), present in whole grains, cereals and vegetable oils, is a lipid-soluble vitamin found in cell membranes and circulating lipoproteins. Its antioxidant capacity acts directly to a variety of ROS. It is found low in AD patients (Jiménez-Jiménez et al., 1997) and although in vitro and animal studies have been encouraging, human trials have produced conflicting results (Berman et al., 2004). A Cochrane study shows that tocopherol is not effective in a prevention trial in mild cognitive impairment (MCI) to reduce progression to AD nor clearly effective in AD patients (Tabet et al., 2000; Luchsinger et al., 2003). Besides, a harmful effect of tocopherol at high doses has also been suggested (Tucker et al., 2005). However, several studies correlate a reduced risk to AD in elderly persons treated with vitamin E and C alone or in combination (Grundman et al., 2004; Morris et al., 1998; 2002; 2005). On the other hand, brain bioavailability of vitamin E in humans is very low and, as suggested elsewhere may not be enough to quickly inhibit AD neuropathology unless administered as a prophylactic at very early ages. The large amount of contradictory data found in literature about the use of vitamins as antioxidants indicates intricate physiological and pharmacological features of AD and remain questionable its use in human.

4.2 Polyphenols and herbal supplements

Polyphenols are a group of plant-derived chemical substances which protect plants from the stress induced by physical damage, disease, radiation and pests (Figure 8). It has been suggested that curcumin, the yellow pigment extracted from the plant *curcuma longa* (turmeric), may be a promising therapy for AD due to its extended neuroprotective actions (Mishra et al., 2008; Cole et al., 2007), including antioxidant, anti-inflammatory, inhibition of A β formation and removal of existing A β , as well as copper and iron chelation. Epigallocatechin-3-gallate (EGCg) is found in green tea and it has been described that prevents A β aggregation by directly binding to the unfolded peptide. It also modulates signal transduction pathways, expression of genes regulating cell survival and apoptosis and its actions in mitochondrial function make it a potent antioxidant (Mandel et al., 2008). Resveratrol is present in red wine, peanuts and other plants and it has been found that it reduces OS, inflammation and A β deposition, decreases cell death and protects DNA (Mishra et al., 2008; Karuppagounder et al., 2009). A recent study suggests that moderate consumption of red wine reduces the risk of developing AD. Nevertheless, the translation to humans is still somewhat problematic and has some caveats since although polyphenols easily penetrate blood-brain barrier, they show bioavailability problems such as low absorption, rapid metabolism and quick elimination. Efforts to increase bioavailability have been reviewed (Anand et al., 2007) and the adjuvant use widely extended (Shoba et al., 1998). Indeed, there is currently a clinical trial underway addressing curcumin bioavailability (<http://clinicaltrials.gov/NCT01001637>). Furthermore, the anti-AD effects of polyphenols may not be mediated solely through their direct antioxidant action but rather indirectly through any other functions. Then, it is still to be clarified whether polyphenols are able to slow the progression of AD. Herbal supplements such as *gingko biloba* have been suggested to possess beneficial properties against AD (Luo et al., 2002). Numerous animal and in vitro studies report that *gingko biloba* extract EGb761 possess neuroprotective benefits (Defeudis et al., 2002) including antioxidant, anti-inflammatory, and regulator of A β processing. It has also been described that *gingko* improves cognitive function in mild to moderate AD patients (Oken et al., 1998; Le Bars et al., 2003) and reduces deterioration in

subjects with more severe dementia via inhibition of the A β induced free radical generation (Napryeyenko et al., 2009; Yao et al., 2001). Nevertheless, a double-blind placebo controlled study found no beneficial effect of *gingko* on dementia in AD patients (Schneider et al, 2005) and DeKosky et al, 2008 showed that *gingko* was not better than placebo at preventing the onset of dementia. Additionally, there are two more studies finding no correlation between cognitive decline and the use of *gingko biloba* (Snitz et al., 2009; Dodge et al., 2008). Although data is controversial, it then appears that *gingko* may be useful delaying cognition impairment but not preventing the onset of AD. The ongoing clinical trial will help to elucidate this question (<http://clinicaltrials.gov/NCT00814346>).

4.3 Mitochondrial-related antioxidants

Since mitochondria are the major sources of ROS in the central nervous system, therapeutic strategies have largely focused in targeting mitochondria and mitochondrial-related pathways. There are several compounds showing an in vitro and in vivo antioxidant and neuroprotective action but only a few have been tested in human clinical trials with mixed results.

4.3.1 Quinone family

Ubiquinone (Coenzyme Q, CoQ) and idebenone, a synthetic analog of CoQ, (Figure 9) are the major mitochondrial targets used as therapeutics against ROS-mediated damage. They have demonstrated antioxidant properties in vitro and in animal models (Wadsworth et al., 2008). CoQ has not been yet tested in humans but idebenone has been investigated in clinical trials for its capacity to inhibit lipid peroxidation. Several studies report a significant effect in memory and attention improvements (Gutzmann et al., 2002; Senin et al., 1992; Weyer et al., 1997) but a larger study reported no effect in slowing the disease progression (Thal et al., 2003).

4.3.2 Other mitochondrial antioxidants

Alpha-lipoic acid (LA) is an organosulfur compound derived from octanoic acid and primarily a cofactor in aerobic metabolism for pyruvate dehydrogenase complex. Its reduced bioactive form produced into cells provides its antioxidant properties (Haenen et al., 1991). Acetyl L-carnitine (ALCAR) is formed within mitochondria by carnitine-O-acetyltransferase. Both LA and ALCAR (Figure 9) are good candidates for being used therapeutically as mitochondrial antioxidants since it was found that a combination of both decreased mitochondrial dysfunction and its consequent ROS-mediated damage in aged rats, improving cognitive functions (Aliev et al., 2009). Additional neuroprotective functions, including binding to targets involved in A β production have been reported (Epis et al., 2008). However, several clinical trials with ALCAR have been conducted with contradictory results: one showed no effectiveness in early onset AD (Thal et al., 2000) whereas another showed a slower deterioration in cognition (Pettergrew et al., 1995). A recent meta-analysis of ALCAR treatment trials showed an improvement in clinical scales in patients with MCI and AD (Montgomery et al., 2003). Dimebon (Figure 9), a non selective antihistamine, possesses several mechanisms of action including the inhibition of A β toxicity and the prevention of ROS-mediated damage (Doody et al., 2009; Okun et al., 2010). Several clinical trials have been performed in AD patients with contradictory results: in a phase 2 clinical trial, dimebon improved cognition and behaviour, overall

function in MCI and AD (Doody et al., 2008) whereas more recently, a phase 3 CONNECTION trial with AD patients showed no improvement in any parameter (<http://clinicaltrials.gov/NCT00675623>).

Fig. 9. Chemical structures of mitochondrial-related antioxidants investigated as promising agents for the treatment of AD.

4.3.3 Monoamine oxidase inhibitors

The therapeutic potential of monoamine oxidase inhibitors (MAOIs) for the treatment of AD has been largely reported (Thomas, 2000; Riederer et al., 2004; Youdim et al., 2005) due to their capacity to reduce the formation of toxic metabolites or oxygen radicals by blocking the catalytic activity of monoamine oxidase (MAO), enzyme located in the mitochondrial membrane and responsible of amine metabolism. It has been extensively reported that MAO-B activity besides increasing with age is found in high levels in AD patients. Selegiline, the classic MAO-B inhibitor, and also other propargylamines (Figure 9) possess potent antioxidant properties (Kitani et al., 2000; Sanz et al., 2004). Moreover, it has also been described that propargylamine-derived MAOIs exert neuroprotective effects by acting in very diverse type of targets, including metal chelation (e.g M30), reduction of A β aggregation and toxicity (Bar-Am et al., 2009; Youdim et al., 2005) as well as direct

actions on diverse mitochondrial-related components. Among this direct functions, propargylamines increase the expression of anti-apoptotic proteins (Akao et al., 2002), prevent cytochrome c release and preserve the mitochondrial membrane potential (Mayurama et al., 2000). The great amount of beneficial functions found for MAOIs make them promising molecules for the treatment of AD. Indeed, current pharmacological challenges in AD involve the design and development of multifunctional compounds able to bind to a very diverse type of targets and among them MAO inhibition is strongly recommended.

4.4 PUFAs

The beneficial effects of omega-3 polyunsaturated fatty acids (PUFAs) have been widely reported which make them good candidates for AD therapy (Cole et al., 2005) since they act directly on intracellular pathways and regulate oxidative stress mechanisms. DHA is the major omega-3 fatty acid in the brain. A recent study although showing no effect of DHA on subjects with mild-to-moderate AD it found a slower rate of cognitive decline among those patients without the APO ε4 allele (Quinn et al., 2009). As reviewed by Mangialasche et al., 2010, some studies have reported a beneficial effect of DHA on cognitive function in patients with AD (Yurko-Mauro et al., 2009; Chiu et al., 2008) whereas others did not find a correlation (Quinn et al., 2009). In effect, a recent study showed that treatment of patients with PUFAs did not modify the neuropathology of this disorder in CSF or plasma, nor the biomarkers of inflammation (Freund-Levi et al., 2009) and a randomised control trial in patients with mild to moderate AD did not delay the rate of cognitive decline (Freund-Levi et al., 2006). Some authors suggest that benefits of omega-3 fatty acids are limited to those with very mild cognitive impairment. A phase 2 randomised clinical trial is currently ongoing (<http://clinicaltrials.gov/NCT01058941>).

4.5 Multiple nutrients

Dietary supplementation with a plethora of nutrients such as apple juice concentrate, red wine, caffeine, fish oil or green tea as well as calorie restriction diets have been conducted. Diverse human studies have shown that multiple formulations improve all measures of cognition, although some authors reported that the increase in memory was not found significant (Chan et al., 2008). A recent study correlates frequent consumption of fruits and vegetables, fish, and omega-3 rich oils with a decreased risk of dementia in AD (Barberger-Gateau et al., 2007). In contrast, interventional trials with antioxidants, B-vitamins and DHA did not give the promising expectations from the epidemiological data. As reported by Von Arnim et al., 2010, although some trials are encouraging, larger randomised clinical trials with combined supplements are needed to draw any conclusion. Supplement composition is still a matter of debate, because high doses of a single antioxidant have been associated with no beneficial effects for AD patients and even with an increase in mortality risk (e.g. vitamin E). Many interventional studies are started very late in the disease state, when AD pathology is already at a fulminant level which severely reduces therapeutic effectiveness of tested agents. The multifactorial nature of AD and the necessity to target the earlier production of OS makes important the combination of multiple supplements. Therefore, studies combining nutrients are of particular interest and at present in progress (e.g. T-diet, NKO™, and Memory XL; <http://clinicaltrials.gov/NCT01192529>, NCT00867828, NCT00903695).

Exposure	Assessment	Design	Case source	Major findings	Reference
EGB 761 (intravenous)	NA	RCT	AD VaD	ADL improvement. Clinical impression of change	Haase et al, 1996
EGB 761 (oral)	NA	RCT	AD VaD	Cognitive improvement	Le Bars et al, 2000
PUFAs	Plasma assay	Cross-sectional	Normal, CI, dementia	Low n-3 and high n-6 associated with CI and AD	Conquer et al, 2000
PUFAs	Plasma assay	Cross-sectional	Normal, CI, dementia	High n-3 associated with CI and AD. Strengthened in ApoEε4 non-carriers	Laurin et al, 2003
PUFAs	Plasma assay	Prospective	Normal	No association between PUFAs and reduced risk of dementia	Kroger et al, 2009
Fish intake	FFQ	Prospective	Normal	Reduced risk of incident dementia	Barberger-Gateau et al, 2002
DHA	Serum assay	Case-control	Normal AD	MMSE and CDR improvement	Tully et al, 2003
Fish oil	FFQ	Prospective	Elderly	Slow rate of decline but not on overall cognitive status	Morris et al, 2005
PUFA	FFQ	Prospective	Elderly	Reduced MMSE decline over 5 years	Van Gelder et al, 2007
β-carotene	NA	Prospective	Elderly	Less cognitive decline only in ApoE4 carriers	Hu et al, 2006
Vitamin E	NA	RCT	MCI	No significant differences compared to placebo or donepezil	Petersen, 2005
α-tocopherol and/or selegiline	NA	RCT	Moderate AD	Longer time to institutionalization in all cases	Sano et al, 1997

Table 2. Studies on antioxidants. EGB 761, Gingko biloba special extract 761; NA, not applicable; VaD, Vascular Disease; ADL, Activities of Daily Living; RCT, Randomised Controlled Trial; ApoE, apolipoprotein E; n-3, omega-3 fatty acids; n-6, omega-6 fatty acids; FFQ, food frequency questionnaire; AD, Alzheimer’s Disease; CI, cognitive impairment; MCI, Mild cognitive impairment; DHA, docohexanoic acid; PUFAs, polyunsaturated fatty acids; MMSE, Folstein Mini- Mental State examination; CDR, Clinical Dementia Rating Scale.

5. Conclusions

Oxidative stress increases with ageing and seems to be a consequence of an imbalance between ROS production and antioxidant defences. The accumulation of endogenous oxygen radicals generated in mitochondria and the consequent oxidative modifications of biological molecules have been indicated as responsible for the ageing process. There is therefore an urgent need to identify biomarkers that would help to diagnose and monitor the early AD or “preclinical AD”. Indeed, a few CSF proteins (e.g. amyloid- β_{1-42} , total tau and phospho-tau) have already shown promise as diagnostic biomarkers for AD. Nevertheless, these biomarkers are not yet optimal diagnostic tools to identify those MCI patients at higher risk of conversion to AD. Thus, a key objective in the research of OS biomarkers is to identify prodromal stages of the disorder, prior to cognitive decline, for gauging the long-term therapeutic effects of drugs. The contradictory results obtained with diverse antioxidants in clinical trials may be explained by other related differences in health problems as well as due to the fact that most studies are very short and conducted with very few subjects. Methodological problems and poorly matched epidemiological studies have also been pointed as reasons for mixed findings. In fact, very few trials are adequately addressing the effect of antioxidants in AD. Although at this time there is no rationale for recommending antioxidant use for prevention or treatment of AD, the current epidemiologic evidence points toward an important role of nutrition in this pathology. The optimal time for prevention seems to be important and still to be determined. Nevertheless, it seems clear that therapies acting in the beginning of the pathological cascade may be more effective than treatments that act after the fact (e.g., removal of amyloid plaques). Then, therapy should begin as early as possible while reversal of cellular pathologies is still achievable. In conclusion, properly addressed studies with antioxidants are greatly needed to obtain convincing data about its beneficial effects as anti-AD. There is also an urgent need for better formulations with increased bioavailability. Due to the multifactorial nature of AD, it seems imperative that future trials may use drug combinations or even multifunctional molecules, rather than a single compound, able to bind to a very diverse type of target and that an antioxidant capacity may be contemplated.

6. Acknowledgment

The authors gratefully acknowledge Professors Nuria Durany (Universitat Internacional de Catalunya) and Peter Riederer (University of Würzburg).

7. References

- Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Münch G. (2005). Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. *J Neurochem*, 92:255-63.
- Aliev G, Liu J, Schenk JC et al. (2009). Neuronal mitochondrial amelioration of alpha-lipoic acid and acetyl-L-carnitine. *J Cell Mol Med*, 13:320-333.
- Akao I. (2002). Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-s and rasagiline. *J Neurochem*, 82:913-923.

- Anand P, Kunnumakkara AB, Newman RA et al. (2007). Bioavailability of curcumin: problems and promises. *Mol Pharm*, 4:807-818.
- Ando Y, Brännström T, Uchida K, Nyhlin N, Näsman B, Suhr O, Yamashita T, Olsson T, El Salhy M, Uchino M, Ando M. (1998). Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. *J Neurol Sci*, Apr 1;156(2):172-6.
- Areosa SA, Sheriff F, Mc Shane R. (2005). Memantine for dementia. *Cochrane Database Syst Rev* (2) CD003154 .
- Bagi Z, CSeko C, Toth E et al. (2003). Oxidative stress-induced dysregulation of arteriosal wall shear stress and blood pressure in hyperhomocysteinemia is prevented by chronic vitamin C treatment. *Am J Physiol Heart Circ Physiol*, 285:H2277-H2283.
- Bar-Am O, Weinreb O, Amit T et al. (2009). The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. *J Mol Neurosci*, 37:135-145.
- Barberger-Gateau P, Letenneur L, Deschamps V et al. (2002). Fish, meat, and risk of dementia: cohort study. *BMJ*, 325(7370):932-933.
- Barberger-Gateau P, Raffaitin C, Letenneur L et al. (2007). Dietary patterns and risk of dementia : The Three-city chort study. *Neurology*, 69(20):1921-1930.
- Barnham KJ, Masters CL, Bush AI. (2004). Neurodegenerative diseases and oxidative stress. *Nat Rev Drug Discov*, Mar;3(3):205-14.
- Basu S. Metabolism of 8-iso-prostaglandin F2alpha. (1998). *FEBS Lett*. May 22;428(1-2):32-6.
- Berman K & Brodaty H. (2004). Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders. *Drugs*, 18:807-825.
- Berlett BS, Stadtman ER. (1997). Protein oxidation in aging, disease, and oxidative stress. *J Biol Chem*. Aug 15;272(33):20313-6.
- Birks J & Harvey R. (2006). Donepezil for dementia due to Alzheimer's disease. *Cochrane Database Syst Rev* (1) CD001190.
- Birks J, Grimley EJ, Iakovidou V et al. (2000). Rivastigmine for Alzheimer's disease. *Cochrane Database Syst Rev* (4) CD001191.
- Bondy SC, Guo-Ross SX, Truong AT. (1998). Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. *Brain Res*, 799:91-96.
- Bradley MA, Markesbery WR, Lovell MA. (2010a). Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. *Free Radic Biol Med*, Jun 15;48(12):1570-6.
- Bradley MA, Xiong-Fister S, Markesbery WR, Lovell MA. (2010b). Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. *Neurobiol Aging*, Oct 19.
- Butterfield DA, Bader Lange ML, Sultana R. (2010). Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. *Biochim Biophys Acta*, Aug;1801(8):924-9.
- Butterfield DA, Castegna A, Lauderback CM, Drake J. (2002). Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. *Neurobiol Aging*, Sep-Oct;23(5):655-64.
- Butterfield DA, Griffin S, Munch G, Pasinetti GM. (2002). Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. *J Alzheimers Dis*, Jun;4(3):193-201.
- Calingasan NY, Uchida K, Gibson GE. (1999). Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. *J Neurochem*, Feb;72(2):751-6.

- Carini M, Aldini G, Facino RM. (2004). Mass spectrometry for detection of 4-hydroxy-trans-2-nonenal (HNE) adducts with peptides and proteins. *Mass Spectrom Rev*, Jul-Aug;23(4):281-305.
- Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. (2002a). Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. *Free Radic Biol Med*, Aug 15;33(4):562-71.
- Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. (2002b). Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. *J Neurochem*, 2002 Sep;82(6):1524-32.
- Castellani RJ, Harris PL, Sayre LM, Fujii J, Taniguchi N, Vitek MP, Founds H, Atwood CS, Perry G, Smith MA. (2001). Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. *Free Radic Biol Med*, Jul 15;31(2):175-80.
- Chan A, Paskavitz J, Remington R et al. (2008). Efficacy of a vitamin/nutraceutical formulation for early stage Alzheimer's disease: a 1 year, open-label pilot study with a 16-month caregiver extension. *Am J Alzheimer Dis Other Dement*, 23:571-585.
- Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD. (2007). RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. *Curr Mol Med*, Dec;7(8):735-42.
- Chiu CC, Su KP, Cheng TC et al. (2008). The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomised double-blind placebo controlled study. *Prog Neuropsychopharmacol Biol Psychiatry*, 32:1538-1544.
- Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA. (1992). 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G----T and A----C substitutions. *J Biol Chem*, Jan 5;267(1):166-72.
- Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW. (2002). Identification of oxidized plasma proteins in Alzheimer's disease. *Biochem Biophys Res Commun*, May 24;293(5):1566-70.
- Cole GM, Teter B, Frautschy SA. (2007). Neuroprotective effects of curcumin. *Adv Exp Med Biol*, 595:197-212.
- Conquer JA, Tierney MC, Zecevic J et al. (2000). Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. *Lipids*, 35(12):1305-1312.
- Cooke MS, Olinski R, Loft S. (2008). European Standards Committee on Urinary (DNA) Lesion Analysis. Measurement and meaning of oxidatively modified DNA lesions in urine. *Cancer Epidemiol Biomarkers Prev*, Jan;17(1):3-14.
- Cracowski JL, Durand T, Bessard G. (2002). Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. *Trends Pharmacol Sci*, Aug;23(8):360-6.
- CTdotgovdimebon ClinicalTrials.gov study NCT00675623, a safety and efficacy study of oral dimebon in patients with mild-to-moderate Alzheimer's disease (CONNECTION)

- Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. (2006a). Biomarkers of oxidative damage in human disease. *Clin Chem*, Apr;52(4):601-23.
- Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A. (2006b). Protein carbonylation, cellular dysfunction, and disease progression. *J Cell Mol Med*, Apr-Jun;10(2):389-406.
- Davidsson P, Paulson L, Hesse C, Blennow K, Nilsson CL. (2001). Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry. *Proteomics*, Mar;1(3):444-52.
- Defeudis FV (2002). Bilobalide and neuroprotection. *Pharmacol Res* 46: 565-568.
- DeKosky ST, Williamson JD, Fitzpatrick AL et al (2008) Gingko biloba for prevention of dementia: a randomised controlled trial. *JAMA*, 300:2253-2262.
- Dodge HH, Zitzelberger T, Oken BS et al. (2008). A randomised placebo-controlled trial of Gingko biloba for the prevention of cognitive decline. *Neurology*, 70:1809-1817.
- Doody RS. (2009). Dimebon as a potential therapy for Alzheimer's disease. *CNS Spectrosc*, 14:14-16;discussion 16-18
- Doody RS, Gavrilova SI, Sano M et al. (2008). Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. *Lancet* 372:207-215
- Epis R, Marcello E, Gardoni F et al. (2008). Modulatory effect of acetyl-L-carnitine on amyloid precursor protein metabolism in hippocampal neurons. *Eur J Pharmacol* 597:51-56
- Eckl PM, Ortner A, Esterbauer H. (1993). Genotoxic properties of 4-hydroxyalkenals and analogous aldehydes. *Mutat Res*. Dec;290(2):183-92.
- Esterbauer H, Schaur RJ, Zollner H. (1991). Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Radic Biol Med*. 11(1):81-128.
- Evans MD, Olinski R, Loft S, Cooke MS. (2010). Toward consensus in the analysis of urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine as a noninvasive biomarker of oxidative stress. European Standards Committee on Urinary (DNA) Lesion Analysis, *FASEB J*. Apr;24(4):1249-60.
- Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T et al. (2006). Omega-3 fatty acids treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomised, double-blind trial. *Arch Neurol*, 63(10):1402-1408.
- Freund-Levi Y, Hjorth E, Lindberg C et al. (2009). Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD Study. *Dement Geriatr Cogn Disord*, 27:481-490.
- Fraga CG, Shigenaga MK, Park JW, Degan P, Ames BN. Oxidative damage to DNA during aging: 8-hydroxy-2'-deoxyguanosine in rat organ DNA and urine. *Proc Natl Acad Sci USA*, 1990 Jun;87(12):4533-7.
- Goodman AB. (2006). Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease. *J Cell Physiol*, 209:598-60.
- Green C, Picot J, Loveman E et al. (2005). Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. *Pharmacoeconomics*, 23:1271-1282.

- Griffiths HR, Møller L, Bartosz G, Bast A, Bertoni-Freddari C, Collins A, Cooke M, Coolen S, Haenen G, Hoberg AM, Loft S, Lunec J, Olinski R, Parry J, Pompella A, Poulsen H, Verhagen H, Astley SB. (2002). Biomarkers. *Mol Aspects Med*, Feb-Jun;23(1-3):101-208.
- Grundman M, Petersen RC, Ferris SH et al. (2004). Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. *Arch Neurol*, 61:59-66.
- Gutzmann H, Khul KP, Hadler D et al. (2002). Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomised, double-blind, parallel group multicenter study. *Pharmacopsychiatry*, 35:12-18.
- Haase J, Halama P and Horr R. (1996). Effectiveness of brief infusions with Gingko biloba Special Extract EGb 761 in dementia of the vascular and Alzheimer type. *Z Gerontol Geriatr*, 29:302-309.
- Haenen GR & Bast A. (1991). Scavenging of hypochlorous acid by lipoic acid. *Biochem Pharmacol*, 42:2244-2246.
- Hamilton ML, Van Remmen H, Drake JA, Yang H, Guo ZM, Kewitt K, Walter CA, Richardson A. (2001). Does oxidative damage to DNA increase with age? *Proc Natl Acad Sci USA*, Aug 28;98(18):10469-74.
- Harman D. (1956). Aging: a theory based on free radical and radiation chemistry. *J Gerontol*, Jul;11(3):298-300.
- Harman D. (1972). The biologic clock: the mitochondria?. *J Am Geriatr Soc*, Apr;20(4):145-7.
- Hu P, Brestky P, Crimmins EM. (2006). Association between serum beta-carotene levels and decline of cognitive function in high functioning older persons with or without apolipoprotein E 4 alleles: MacArthur studies of successful aging. *J Gerontol A Biol Sci Med Sci*, 61:616-620.
- Jiménez-Jiménez FJ, de Bustos F, Molina JA et al. (1997). Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease. *J Neural Transm*, 104:703-710.
- Karuppagounder SS, Pinto JT, Xu H et al. (2009). Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. *Neurochem Int*, 54:111-118.
- Kim KM, Jung BH, Paeng KJ, Kim I, Chung BC. (2004). Increased urinary F(2)-isoprostanes levels in the patients with Alzheimer's disease. *Brain Res Bull*, Jul 30;64(1):47-51.
- Kimura T, Takamatsu J, Ikeda K, Kondo A, Miyakawa T, Horiuchi S. (1996). Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons. *Neurosci Lett*, Apr 12;208(1):53-6.
- Kitani KA et al. (2000). Common properties for propargylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: implications for the life prolonging effect of (-)-deprenyl. *J Neural Transm*, 60 (Suppl) 139-156.
- Korolainen MA, Nyman TA, Nyyssönen P, Hartikainen ES, Pirttilä T. (2007). Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease. *Clin Chem*, Apr;53(4):657-65.
- Korolainen MA, Goldsteins G, Nyman TA, Alafuzoff I, Koistinaho J, Pirttilä T. (2006). Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. *Neurobiol Aging*, Jan;27(1):42-53.

- Kozekov ID, Nechev LV, Moseley MS, Harris CM, Rizzo CJ, Stone MP, Harris TM. (2003). DNA interchain cross-links formed by acrolein and crotonaldehyde. *J Am Chem Soc*, Jan 8;125(1):50-61.
- Kroger E, Verreault R, Carmichael PH et al. (2009). Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. *Am J Clin Nutr*, 90(1):184-192.
- Laurin D, Verreault R, Lindsay J et al. (2003). Omega-3 fatty acids and risk of cognitive impairment and dementia. *J Alzheimers Dis* 5(4):315-322.
- Ledesma MD, Pérez M, Colaco C et al (1998) Tau glycation is involved in aggregation of the protein but not in the formation of filaments. *Cell Moll Biol* Nov 44(7):1111-1116.
- Liu X, Lovell MA, Lynn BC. (2006). Detection and quantification of endogenous cyclic DNA adducts derived from trans-4-hydroxy-2-nonenal in human brain tissue by isotope dilution capillary liquid chromatography nanoelectrospray tandem mass spectrometry. *Chem Res Toxicol*, May;19(5):710-8.
- Le Bars PL, Kieser M and Itil KZ. (2000). A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. *Dement Geriatr Cogn Disord*, 11:230-237.
- Le Bars PL. (2003). Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles. *Pharmacopsychiatry*, 36 (Suppl 1) S50-S55.
- Loske C, Gerdemann A, Schepl W, Wycislo M, Schinzel R, Palm D, Riederer P, Münch G. (2000). Transition metal-mediated glycooxidation accelerates cross-linking of beta-amyloid peptide. *Eur J Biochem*, Jul;267(13):4171-8.
- Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. (1997). Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. *Neurobiol Aging*, Sep-Oct;18(5):457-61.
- Lovell MA, Markesbery WR. (2007a). Oxidative damage in mild cognitive impairment and early Alzheimer's disease. *J Neurosci Res*, Nov 1;85(14):3036-40.
- Lovell MA, Markesbery WR. (2007b). Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. *Nucleic Acids Res*, 35(22):7497-504.
- Lovell MA, Markesbery WR. (2001). Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. *Arch Neurol*, Mar;58(3):392-6.
- Loy C & Schneider L. (2004). Galantamine for Alzheimer's disease. *Cochrane Database Syst Rev*, (4)CD001747.
- Luchsinger JA, Tang MX, Shea S et al. (2003). Antioxidant vitamin intake and risk of Alzheimer disease. *Arch Neurol*, 60:203-208.
- Luo Y, Smith JV, Paramasivam V et al. (2002). Inhibition of amyloid beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb 761. *Proc Natl Acad Sci USA*, 99-12197-12202.
- Mandel SA, Amit T, Kalfon L. (2008). Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). *J Alzheimer Dis*, 17:681-697.
- Mangialasche F, Solomon A, Winblad B et al. (2010). Alzheimer's disease: clinical trials and drug development. *Lancet Neurol* 9:702-716.
- Markesbery WR, Lovell MA. (1998). Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. *Neurobiol Aging*, Jan-Feb;19(1):33-6.
- Markesbery WR, Carney JM. (1999). Oxidative alterations in Alzheimer's disease. *Brain Pathol*, Jan;9(1):133-46.

- Mayurama W, Akao Y, Youdim MB et al. (2000). Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of GAPDH induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. *J Neurochem*, 78:727-735.
- McGrath LT, McGleenon BM, Brennan S, McColl D, McIlroy S, Passmore AP. (2001). Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. *QJM*, Sep;94(9):485-90.
- McIlroy SP, Dynan KB, Lawson JT et al. (2002). Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia and Alzheimer disease in Northern Ireland. *Stroke*, 33:2351-2356
- Mecocci P, Polidori MC, Cherubini A, Ingegneri T, Mattioli P, Catani M, Rinaldi P, Cecchetti R, Stahl W, Senin U, Beal MF. (2002). Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. *Arch Neurol*, May;59(5):794-8.
- Migliore L, Fontana I, Trippi F, Colognato R, Coppedè F, Tognoni G, Nucciarone B, Siciliano G. (2005). Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. *Neurobiol Aging*, May; 26(5):567-73.
- Mishra S & Palanivelu K. (2008). The effect of curcumin (turmeric) on Alzheimer's disease: an overview. *Ann Indian Acad Neurol*, 11:13-19.
- Montgomery SA, Thal LJ & Amrein R. (2003). Meta-analysis of double-blind randomised controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. *Int Clin Psychopharmacol*, 18:61-71.
- Montine KS, Kim PJ, Olson SJ, Markesbery WR, Montine TJ. (1997). 4-hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. *J Neuropathol Exp Neurol*, 56(8): 866-71.
- Montine TJ, Markesbery WR, Morrow JD, Roberts LJ 2nd. (1998). Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. *Ann Neurol*, Sep;44(3):410-3.
- Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, Terry E, Roberts LJ 2nd, Kaye JA, Morrow JD. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. *Ann Neurol*, 2002 Aug;52(2):175-9.
- Montine TJ, Peskind ER, Quinn JF, Wilson AM, Montine KS, Galasko D. Increased Cerebrospinal Fluid F(2)-Isoprostanes are Associated with Aging and Latent Alzheimer's Disease as Identified by Biomarkers. *Neuromolecular Med*, 2011 Mar;13(1):37-43.
- Montuschi P, Barnes PJ, Roberts LJ 2nd. Isoprostanes: markers and mediators of oxidative stress. *FASEB J*, 2004 Dec; 18(15):1791-800.
- Morris MC, Beckett LA, Scherr PA et al (1998) Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. *Alzheimer Dis assoc Disord*,12:121-126.
- Morris MC, Evans DA, Bienias JL et al (2002) Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. *J Am Med Assoc*, 287:3230-3237.
- Morris MC, Evans DA, Bienias JL et al (2003). Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. *Arch Neurol*, 60(7):940-946.
- Morris MC, Evans DA, Tagney CC (2005) Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. *Am J Clin Nutr*, 81:508-514.

- Morris MC, Evans DA, Tagney CC et al. (2005). Fish consumption and cognitive decline with age in a large community study. *Arch Neurol*, 62(12):1849-1853.
- Morris MS, Jacques PF, Rosenberg IH et al. (2007). Folate and vitamin B12 status in relation to anemia, macrocytosis and cognitive impairment in older Americans in the age of folic acid fortification. *Am J Clin Nutr*, 85:193-200.
- Morrow JD, Tapper AR, Zackert WE, Yang J, Sanchez SC, Montine TJ, Roberts LJ. (1999). Formation of novel isoprostane-like compounds from docosahexaenoic acid. *Adv Exp Med Biol*, 469:343-7.
- Napryeyenko O, Sonnik G, Tartakovsky I. (2009). Efficacy and tolerability of ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial. *J Neurol Sci*, 283:224-229.
- Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. (2001). Oxidative damage is the earliest event in Alzheimer disease. *J Neuropathol Exp Neurol*, Aug;60(8):759-67.
- Oken BS, Storzbach DM, Kaye JA. (1998). The efficacy of Ginkgo biloba on cognitive function in Alzheimer's disease. *Arch Neurol*, 55:1409-1415.
- Okun I, Tkachenko SE, Khvat A et al. (2010). From anti-allergic to anti-Alzheimer's: molecular pharmacology of dimebon. *Curr Alzheimer Res*, 7:97-112.
- Olinski R, Siomek A, Rozalski R, Gackowski D, Foksinski M, Guz J, Dziaman T, Szpila A, Tudek B. (2007). Oxidative damage to DNA and antioxidant status in aging and age-related diseases. *Acta Biochim Pol*, 54(1):11-26.
- Perry G, Raina AK, Nunomura A, Wataya T, Sayre LM, Smith MA. (2000). How important is oxidative damage? Lessons from Alzheimer's disease. *Free Radic Biol Med*, Mar 1;28(5):831-4.
- Perry G, Nunomura A, Cash AD, Taddeo MA, Hirai K, Aliev G, Avila J, Wataya T, Shimohama S, Atwood CS, Smith MA. (2002). *Reactive oxygen: its sources and significance in Alzheimer disease*. *J Neural Transm Suppl*, (62):69-75.
- Petersen RC, Thomas RG, Grudman N et al. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. *N Engl J Med* 352:2379-2388.
- Pettersgrew JW, Klunk WE, Panchalingam K et al, (1995). Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. *Neurobiol Aging*, 16:1-4.
- Praticò D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. (2002). Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. *Arch Neurol*, Jun;59(6): 972-6.
- Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. (2003). Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. *Brain Res Mol Brain Res*, Oct 21;118(1-2):140-6.
- Quinn JF, Raman R, Thomas RG et al. (2009). A clinical trial of docosahexanoic acid (DHA) for the treatment of Alzheimer's disease. *Alzheimers Assoc Int Conf Alzheimer Dis*; July 12.
- Riederer P, Danielczyk W, Grünblatt E. (2004). Monoamine oxidase-B inhibition in Alzheimer's disease. *Neurotoxicology*, 25 (1-2):271-277.
- Roberts LJ 2nd, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, Morrow JD. (1998). Formation of isoprostane-like compounds

- (neuroprostanes) in vivo from docosahexaenoic acid. *J Biol Chem*, May 29;273(22):13605-12.
- Sahin M, Karauzum SB, Perry G et al. (2005). Retinoic acid isomers protect hippocampal neurons from amyloid-beta induced neurodegeneration. *Neurotox Res*, 7:243-250.
- Sano M, Ernesto C, Thomas RG et al. (1997). A controlled trial of selegiline, alpha tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. *N Engl J Med*, 336:1216-1222.
- Sanz E, Romera M, Bellik L et al. (2004). Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease. *Med Sci Monit*, 10(12):BR477-484.
- Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. (1997). 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. *J Neurochem*, May;68(5):2092-7.
- Schneider LS, DeKosky ST, Farlow MR et al. (2005). A randomised, double-blind, placebo controlled trial of two doses of Gongko biloba extract in dementia of the Alzheimer's type. *Curr Alzheimer Res*, 2 541-551.
- Senin U, Parnetti L, Barbagallo-Sangiorgi G et al. (1992). Idebenone in senile dementia of Alzheimer type:a multicenter study. *Arch Gerontol Geriatr*, 15:249-260.
- Shigenaga MK, Gimeno CJ, Ames BN. (1989). Urinary 8-hydroxy-2'-deoxyguanosine as a biological marker of in vivo oxidative DNA damage. *Proc Natl Acad Sci USA*, Dec;86(24):9697-701.
- Shoba G, Joy S, Joseph T et al. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Med*, 64:353-356.
- Smith MA, Sayre LM, Monnier VM, Perry G. (1995). Radical AGEing in Alzheimer's disease. *Trends Neurosci*, Apr;18(4):172-6.
- Snitz BE, O'Meara ES, Carlsson MC et al. (2009). Ginkgo biloba for preventing cognitive decline in older adults: a randomised trial. *JAMA*, 302:2663-2670.
- Southern L, Williams J, Esiri MM. (2007). Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia. *BMC Neurol*, Oct 16;7:35.
- Sultana R, Butterfield DA. (2011). Identification of the oxidative stress proteome in the brain. *Free Radic Biol Med*, Feb 15;50(4):487-94. Epub 2010 Nov 25.
- Tabet N, Birks J, Grimley EF. (2000). Vitamine E for Alzheimer's disease. *Cochrane database Syst Rev* (4) CD002854.
- Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo DG, Mattson MP, Tabaton M. (2008). Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. *J Neurochem*, Feb;104(3):683-95.
- Thal LJ, Grundman M, Berg J et al. (2003). Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. *Neurology*, 61:1498-1502.
- Thal LJ, Calvani M, Amato A et al. (2000). A 1-year controlled trial of acetyl-L-carnitine in early onset AD. *Neurology*, 55:805-810.
- Thomas T. (2000). Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. *Neurobiol Aging*, 21(2):343-348.

- Thome J, Münch G, Muller R, Schinzel R, Kornhuber J, Blum-Degen D et al. (1996). Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer's disease. *Neurotox Res*, 4:191-209.
- Tucker JM & Townsend DM. (2005). Alpha-tocopherol: roles in prevention and therapy of human disease. *Biomed Pharmacother*, 59 (7):380-387.
- Tully AM, Roche HM, Doyle R et al. (2003). Low serum cholesteryl ester-docohexanoic acid levels in Alzheimer's disease: a case-control study. *Br J Nutr*, 89(4):483-489.
- Uchida K. (2003). 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. *Prog Lipid Res*, Jul;42(4):318-43.
- Van Gelder BM, Tijhuis M, Kalmijn S et al. (2007). Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. *Am J Clin Nutr*, 85(4):1142-1147.
- Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A. (1994). Advanced glycation end products contribute to amyloidosis in Alzheimer disease. *Proc Natl Acad Sci USA*, May 24;91(11):4766-70.
- Von Arnim CA, Gola U and Biesalski HK. (2010). More than the sum of its parts? Nutrition in Alzheimer's disease. *Nutrition*, 26(7-8):694-700.
- Wadsworth TL, Bishop JA, Pappu AS et al. (2008). Evaluation of Coenzyme Q as an antioxidant strategy for Alzheimer's disease. *J Alzheimer's Dis*, 14:225-234.
- Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PL, Shimohama S, Szwedda LI, Kaminski MA, Avila J, Price DL, Cleveland DW, Sayre LM, Perry G. (2002). High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. *J Biol Chem*, Feb 15;277(7):4644-8.
- Weyer G, Babej. Dolle RM, Hadler D et al. (1997). A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. *Neuropsychobiology*, 36:73-82.
- White AR, Barnham KJ, Huang X et al. (2004). Iron inhibits neurotoxicity induced by trace copper and biological reductants. *J Biol Inorg Chem*, 9:269-280.
- Williams TL, Lynn BC, Markesbery WR, Lovell MA. (2006). Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. *Neurobiol Aging*, Aug;27(8):1094-9.
- Yao Z & Drieu V. (2001). Papadopoulos, the Ginkgo biloba extract Egb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. *Brain Res*, 889:181-190.
- Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, Scott CW, Caputo C, Frappier T, Smith MA, et al. (1994). Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. *Proc Natl Acad Sci USA*, Aug 2;91(16):7787-91.
- Youdim BM, Fridkin M and Zheng H. (2005). Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK28 as a more effective approach to treatment of brain aging and aging neurodegenerative diseases. *Mech Aging Dev*, 126: 317-326.
- Yu HL, Chertkow HM, Bergman H, Schipper HM. (2003). Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. *Proteomics*, Nov;3(11):2240-8.

Yurko-Mauro K, McCarthy D, Bailey-Hall E et al. (2009). Results of the MIDAS trial: effects of docohexanoic acid on physiological and safety parameters in age-related cognitive decline. *Alzheimers Assoc Int Conf Alzheimer Dis*; July 12.

IntechOpen

IntechOpen

Alzheimer's Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets

Edited by Dr. Suzanne De La Monte

ISBN 978-953-307-690-4

Hard cover, 686 pages

Publisher InTech

Published online 12, September, 2011

Published in print edition September, 2011

Alzheimer's Disease Pathogenesis: Core Concepts, Shifting Paradigms, and Therapeutic Targets, delivers the concepts embodied within its title. This exciting book presents the full array of theories about the causes of Alzheimer's, including fresh concepts that have gained ground among both professionals and the lay public. Acknowledged experts provide highly informative yet critical reviews of the factors that most likely contribute to Alzheimer's, including genetics, metabolic deficiencies, oxidative stress, and possibly environmental exposures. Evidence that Alzheimer's resembles a brain form of diabetes is discussed from different perspectives, ranging from disease mechanisms to therapeutics. This book is further energized by discussions of how neurotransmitter deficits, neuro-inflammation, and oxidative stress impair neuronal plasticity and contribute to Alzheimer's neurodegeneration. The diversity of topics presented in just the right depth will interest clinicians and researchers alike. This book inspires confidence that effective treatments could be developed based upon the expanding list of potential therapeutic targets.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Alejandro Gella and Irene Bolea (2011). Oxidative Stress in Alzheimer's Disease: Pathogenesis, Biomarkers and Therapy, Alzheimer's Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets, Dr. Suzanne De La Monte (Ed.), ISBN: 978-953-307-690-4, InTech, Available from:
<http://www.intechopen.com/books/alzheimer-s-disease-pathogenesis-core-concepts-shifting-paradigms-and-therapeutic-targets/oxidative-stress-in-alzheimer-s-disease-pathogenesis-biomarkers-and-therapy>

INTeCH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License](https://creativecommons.org/licenses/by-nc-sa/3.0/), which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.

IntechOpen

IntechOpen